Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Reevaluation of the 2-Year Protocol for Treating Canine Lymphosarcoma
Canine lymphosarcomas are common neoplasias which tend to respond very well to chemotherapy. Various treatment protocols are used worldwide, and the 2-year-protocol of the University of Wisconsin is a common one. This interesting study reevaluates the data of nearly 100 dogs...

This retrospective study investigated a population of 96 dogs with newly diagnosed malignant lymphosarcoma that were treated with the commonly used University of Wisconsin-Madison (UW-M) chemotherapy protocol.

Pretreatment characteristics were analyzed to determine prognostic factors.

Dogs with higher World Health Organization (WHO) stages (including stage IV) and dogs with hypercalcemia were at significantly higher risk of relapse (P=0.018 and P=0.016, respectively).

Dose reduction, treatment delays, and prior therapy with cortico-steroids were not associated with clinical outcome.
First remission duration of 270 days was similar to historically reported data.

Overall survival time of 218 days was much shorter than historical data.



Source: Claire Inderbinen Kaiser, Janean L. Fidel, Malgorzata Roos, Barbara Kaser-Hotz (2007): Reevaluation of the University of Wisconsin 2-Year Protocol for Treating Canine Lymphosarcoma. In: Journal of the American Animal Hospital Association 43:85-92 (2007)





Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Fluorescein sodium-guided resection of intracranial lesions in dogsmembers
Twenty-two dogs with intracranial lesions were enrolled in this prospective case series. The objectives were to evaluate the safety of an intraoperative fluorescein sodium (FS) injection and elucidate the relationships between the MRI findings, pathological diagnoses, and intraoperative staining characteristics of intracranial lesions in 22 dogs.

  • Chemosensitivity of feline injection site-associated sarcoma cell lines to carboplatin
  • Ultrasound and clinical findings in cats with urethral obstructionmembers
  • Novel technique to measure plasma lipids in diabetic dogsmembers
  • Prevalence and disease associations in feline thrombocytopeniamembers
  • Optic neuritis in dogs: an updatemembers
  • Brachycephalic airway syndrome - differences between pugs and French bulldogsmembers
  • Prognostic factors in cats with HCMmembers
  • Ureteral Papilla Implantation in Cats Undergoing Renal Transplantationmembers
  • Storage lesion in canine packed erythrocytesmembers
  • Drug-induced infiltrative lung disease with cytarabine and prednisonemembers
  • Laparoscopic-assisted Gastropexy and the Gastrointestinal Transit Time in Dogsmembers
  • Transpalpebral ultrasonographic evaluation and measurement of the optic nerve members


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2016 VetContact GmbH
    All rights reserved